These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9085739)

  • 1. Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice.
    Brok HP; Vossen JM; Heidt PJ
    Bone Marrow Transplant; 1997 Mar; 19(6):601-6. PubMed ID: 9085739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-gamma-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells.
    Brok HP; Vossen JM; Heidt PJ
    Bone Marrow Transplant; 1998 Nov; 22(10):1005-10. PubMed ID: 9849699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice.
    Brok HP; Heidt PJ; van der Meide PH; Zurcher C; Vossen JM
    J Immunol; 1993 Dec; 151(11):6451-9. PubMed ID: 8245478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
    Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
    Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
    Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
    Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice.
    Eto M; Mayumi H; Tomita Y; Yoshikai Y; Nishimura Y; Maeda T; Ando T; Nomoto K
    J Immunol; 1991 Mar; 146(5):1402-9. PubMed ID: 1671578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced tolerance to allografts in mice. IX. Establishment of complete chimerism by allogeneic spleen cell transplantation from donors made tolerant to H-2-identical recipients.
    Mayumi H; Himeno K; Tanaka K; Tokuda N; Fan JL; Nomoto K
    Transplantation; 1986 Oct; 42(4):417-22. PubMed ID: 3532453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immunologic tolerance induction in chimeric mice after bone marrow transplantation across major histocompatibility barriers: persistent or redeveloping immunologic responsiveness after prolonged survival.
    Sugiura K; Yasumizu R; Iwai H; Inaba MM; Toki J; Ogura M; Hara I; Good RA; Ikehara S
    Thymus; 1991 Nov; 18(3):137-53. PubMed ID: 1838450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
    Davenport C; George T; Devora GA; Morris MA; Gordon BE; Kumar V; Bennett M
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):294-303. PubMed ID: 9502296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratinocytes synthesize Ia antigen in acute cutaneous graft-vs-host disease.
    Breathnach SM; Katz SI
    J Immunol; 1983 Dec; 131(6):2741-5. PubMed ID: 6417231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens.
    Thiele DL; Calomeni JA; Lipsky PE
    J Immunol; 1987 Oct; 139(7):2137-42. PubMed ID: 3309052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of cyclosporine-induced syngeneic graft-versus-host disease in bone marrow transplantation by UV-B irradiated bone marrow cells.
    Ohajekwe OA; James T; Hardy MA; Oluwole SF
    Bone Marrow Transplant; 1995 Apr; 15(4):627-32. PubMed ID: 7655391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.
    Tang W; Yang Y; Zhang F; Li YC; Zhou R; Wang JX; Zhu YN; Li XY; Yang YF; Zuo JP
    Int Immunopharmacol; 2005 Dec; 5(13-14):1904-13. PubMed ID: 16275625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.